BRPI0814931A2 - Composto com atividade contra hcv, sua composição e seu uso - Google Patents

Composto com atividade contra hcv, sua composição e seu uso

Info

Publication number
BRPI0814931A2
BRPI0814931A2 BRPI0814931-3A2A BRPI0814931A BRPI0814931A2 BR PI0814931 A2 BRPI0814931 A2 BR PI0814931A2 BR PI0814931 A BRPI0814931 A BR PI0814931A BR PI0814931 A2 BRPI0814931 A2 BR PI0814931A2
Authority
BR
Brazil
Prior art keywords
composite
composition
hcv activity
hcv
activity
Prior art date
Application number
BRPI0814931-3A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Scott W Martins
Carl P Bergstrom
Robert G Gentles
Kap-Sun Yeung
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0814931A2 publication Critical patent/BRPI0814931A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0814931-3A2A 2007-08-09 2008-08-01 Composto com atividade contra hcv, sua composição e seu uso BRPI0814931A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US95481407P 2007-08-09 2007-08-09
US4994408P 2008-05-02 2008-05-02
US12/180,994 US7652004B2 (en) 2007-08-09 2008-07-28 Compounds for the treatment of hepatitis C
PCT/US2008/071881 WO2009029384A2 (en) 2007-08-09 2008-08-01 Compounds for the treatment of hepatitis c

Publications (1)

Publication Number Publication Date
BRPI0814931A2 true BRPI0814931A2 (pt) 2015-02-03

Family

ID=40261456

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814931-3A2A BRPI0814931A2 (pt) 2007-08-09 2008-08-01 Composto com atividade contra hcv, sua composição e seu uso

Country Status (18)

Country Link
US (1) US7652004B2 (enExample)
EP (1) EP2183252B1 (enExample)
JP (1) JP5465670B2 (enExample)
KR (1) KR20100066492A (enExample)
CN (1) CN101821267B (enExample)
AR (1) AR067897A1 (enExample)
AU (1) AU2008293845B2 (enExample)
BR (1) BRPI0814931A2 (enExample)
CA (1) CA2695781A1 (enExample)
CL (1) CL2008002353A1 (enExample)
CO (1) CO6251359A2 (enExample)
EA (1) EA015978B1 (enExample)
MX (1) MX2010001416A (enExample)
NZ (1) NZ583149A (enExample)
PE (1) PE20090618A1 (enExample)
TW (1) TW200906418A (enExample)
WO (1) WO2009029384A2 (enExample)
ZA (1) ZA201000923B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2005049622A1 (ja) * 2003-11-19 2007-06-07 日本たばこ産業株式会社 ５−５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途
US20070049593A1 (en) * 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
MX2010005226A (es) * 2007-11-20 2010-05-27 Bristol Myers Squibb Co Inhibidores de ns5b de hcv de indolobenzazepina fusionados a ciclopropilo.
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8431568B2 (en) 2008-03-27 2013-04-30 Bristol-Myers Squibb Company Aromatic heterocyclic fused indolobenzadiazepine HCV NS5B inhibitors
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2396329B1 (en) * 2009-02-11 2014-10-29 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
JP5918264B2 (ja) 2010-12-22 2016-05-18 アッヴィ・インコーポレイテッド Ｃ型肝炎阻害剤およびその使用
CH706864B1 (de) 2011-06-22 2016-03-31 Central Glass Co Ltd Verfahren zur Herstellung einer Pyrazol-Verbindung.
JP5915004B2 (ja) * 2011-06-22 2016-05-11 セントラル硝子株式会社 ピラゾール化合物の製造方法
BR112015000714A2 (pt) * 2012-07-18 2017-06-27 Bristol Myers Squibb Holdings Ireland processos e intermediários para a preparação de (4bs,5ar)-12-ciclo-hexil-n-(n,n-dimetilsulfamoil)-3-metóxi-5a-((1r,5s)-3-metil-3,8-diazabiciclo[3.2.1]octano-8-carbonil)-4b,5,5a, 6-tetra-hidrobenzo [3,4]ciclopropa[5,6]azepino[1,2-a] indol-9-carboxamida

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
CA2585113A1 (en) 2004-10-26 2006-05-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
US7399758B2 (en) 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7473688B2 (en) 2005-09-13 2009-01-06 Bristol-Myers Squibb Company Indolobenzazepine HCV NS5B inhibitors
US7456165B2 (en) 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
CN101490054B (zh) 2006-05-25 2012-05-16 百时美施贵宝公司 环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂
WO2007140200A2 (en) 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US7452876B2 (en) 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7521444B2 (en) 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538102B2 (en) 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7541353B2 (en) 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7538103B2 (en) 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C

Also Published As

Publication number Publication date
MX2010001416A (es) 2010-03-01
AU2008293845A1 (en) 2009-03-05
JP2010535787A (ja) 2010-11-25
CA2695781A1 (en) 2009-03-05
NZ583149A (en) 2011-07-29
CN101821267B (zh) 2013-07-10
US20090074715A1 (en) 2009-03-19
CN101821267A (zh) 2010-09-01
EA201000277A1 (ru) 2010-06-30
TW200906418A (en) 2009-02-16
EP2183252B1 (en) 2015-01-14
KR20100066492A (ko) 2010-06-17
US7652004B2 (en) 2010-01-26
WO2009029384A2 (en) 2009-03-05
EA015978B1 (ru) 2012-01-30
PE20090618A1 (es) 2009-05-16
CO6251359A2 (es) 2011-02-21
EP2183252A2 (en) 2010-05-12
AR067897A1 (es) 2009-10-28
JP5465670B2 (ja) 2014-04-09
CL2008002353A1 (es) 2008-10-24
WO2009029384A3 (en) 2009-05-28
AU2008293845B2 (en) 2013-02-14
ZA201000923B (en) 2011-04-28

Similar Documents

Publication Publication Date Title
BRPI0814931A2 (pt) Composto com atividade contra hcv, sua composição e seu uso
BRPI0808098A2 (pt) 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas e seu uso
BRPI0718192A2 (pt) Corantes dispersos, sua preparação e seu uso.
BRPI1011521A2 (pt) Composto de hidrazida e uso do mesmo no controle de pragas.
BRPI0913264A2 (pt) copoliamida, composição compreendendo tal copoliamida e seu uso
BRPI1010957A2 (pt) variantes de celulase com expressão, atividade e/ou estabilidade aprimorada e uso das mesmas.
BRPI0919438A2 (pt) mistura de poliésteres, e, uso das misturas de poliésteres
BRPI0821276A2 (pt) Produto, e, uso do produto
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
BRPI0918789A2 (pt) variantes de beta-glicosidase tendo atividade melhorada, e uso das mesmas
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BRPI0819299A2 (pt) Uso de composição, e, composição contendo proteína
BRPI0719345A2 (pt) Di-hidroimidazóis substituídos e seu uso no tratamento de tumores.
EP2165609A4 (en) MEANS FOR IMPROVED PANSEN FERMENTATION
BRPI0806589A2 (pt) Catalisador, sua preparação e uso.
BRPI0813263A2 (pt) Oxazolidinonas substituídas e seu uso
BRPI0915552A2 (pt) derivados de ciclosporina, seu uso e sua composição farmacêutica
BRPI0808798A2 (pt) Fenoxifenilamidinas 3,5-dissubstituídas e seu uso como fungicidas
BRPI0816372A2 (pt) Ácidos 6-fenilnicotínicos substituídos e seu uso
BRPI0818641A2 (pt) Rótulo, e, uso do rótulo
BRPI0921441A2 (pt) liga de cobre-estanho, material composto e uso
BRPI0812766A2 (pt) 4-cloro-4-alcóxi-1,1,1-triflúor-2-butanonas, preparação das mesmas e uso das mesmas no preparo de 4-alcóxi-1,1,1-triflúor-3-buten-2-onas
BRPI0911772A2 (pt) composto, composição farmacêutica, e, uso do composto.
BRPI0907053A2 (pt) Poliisobutenoamina, composição combustível, e, uso de poliisobutenoaminas
BRPI0908786A2 (pt) Composição de material com estrutura porosa, métodos de preparação e usos correspondentes

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.